Sumatriptan

Sumatriptan is an abortive antimigraine drug, meaning it is taken to stop an attack that has already begun rather than to prevent one. It belongs to the triptan family, a group of selective serotonin receptor agonists developed specifically for migraine ^[1]. Chemically it resembles the neurotransmitter serotonin and acts on particular serotonin receptor subtypes in the blood vessels and nerves of the head ^[2].

Sumatriptan was the first triptan to reach the market, developed by Glaxo and approved for medical use in the early 1990s ^[1]. Its arrival marked a turning point in migraine treatment, offering a drug designed around an emerging understanding of the disorder rather than borrowed from other uses, and it opened the way for a whole class of related medicines ^[1]. It has since become a widely used generic drug.

The drug is used to treat acute migraine attacks, with or without aura, and to abort cluster headaches ^[2]. It comes in several forms, including oral tablets, a subcutaneous injection, and a nasal spray; the injection acts fastest and is especially useful for cluster headache and when nausea makes tablets impractical. Systematic reviews confirm that oral sumatriptan is an effective abortive treatment that relieves headache pain and associated symptoms such as nausea and light sensitivity, and that treating early, while pain is still mild, works better ^[3]. Combining it with the anti-inflammatory drug naproxen provides somewhat greater relief than either alone ^[4].

Sumatriptan is a prescription medicine. Because it constricts blood vessels, it is not suitable for everyone; it is contraindicated in people with coronary artery disease, a history of stroke, uncontrolled high blood pressure, and certain uncommon migraine types, and it should not be combined with ergot-type drugs or other triptans within a short interval ^[2]. Common side effects include tingling, warmth, flushing, dizziness, and a sensation of tightness in the chest or throat, which are usually mild and short-lived. Frequent use of any acute migraine drug can lead to medication-overuse headache, and rare serious reactions include coronary spasm and serotonin syndrome.

Sumatriptan is a prescription drug. The most common experiences are a tightness or pressure in the chest, throat, jaw, or neck, along with tingling, flushing, a feeling of warmth, dizziness, and reactions at the injection site; these so-called triptan sensations are usually harmless but can feel alarmingly like heart symptoms. It must not be used by people with coronary artery disease, a prior heart attack or stroke, uncontrolled high blood pressure, or hemiplegic or basilar migraine, and it should not be taken within 24 hours of an ergot drug or another triptan. Combining it with SSRI or SNRI antidepressants carries a risk of serotonin syndrome. Using it too many days a month can backfire into medication-overuse headache.

Sumatriptan is metabolized mainly by monoamine oxidase A, so MAO-A inhibitors including phenelzine, tranylcypromine and moclobemide raise its exposure severalfold; the oral form is contraindicated with them, and the effect persists for about two weeks after an MAO inhibitor is stopped.

Ergotamine, dihydroergotamine and other triptans constrict vessels through overlapping 5-HT1B receptors, so taking them close together compounds the vasoconstriction and the risk of coronary or peripheral ischemia.

The serotonin syndrome question is the one most often raised. Regulators issued an advisory in 2006 about triptans combined with SSRIs and SNRIs, and case reports exist, but later systematic reviews found the incidence very low and the causal link uncertain, partly because sumatriptan acts at 5-HT1 receptors rather than the 5-HT2A receptor most implicated in the syndrome. Sumatriptan has no meaningful cytochrome P450 interactions.

Checking a whole stack? Run it through interactions + stacks.

Sumatriptan was developed by the British pharmaceutical company Glaxo through a research program led by the pharmacologist Patrick Humphrey, which set out in the late 1970s and 1980s to design a selective serotonin receptor agonist that could abort migraine attacks. The team pursued the idea that stimulating specific serotonin receptors on cranial blood vessels and nerves could relieve the pain of migraine, and their work yielded the first agent of an entirely new class later named the triptans.

Sumatriptan was first approved in the United Kingdom in 1991 and reached the United States market in 1992 to 1993, initially as a subcutaneous injection and later as tablets and nasal sprays. Its introduction transformed acute migraine care, which had previously relied on ergot compounds and general analgesics. Sumatriptan is now available as an inexpensive generic and appears on the World Health Organization's list of essential medicines.

Sumatriptan is widely regarded as a breakthrough that redefined the acute treatment of migraine, and it remains the reference standard against which newer therapies are measured. Patients and neurologists value its ability to stop an attack in progress rather than merely dulling the pain, with the subcutaneous injection in particular ranking among the fastest and most effective options for severe migraine and cluster headache. Decades of trials and real-world use have given it an established and reassuring safety record for the great majority of users. Honest counseling notes that it works best taken early in an attack, does not prevent migraines, and is not suitable for people with certain cardiovascular conditions because of its vessel-narrowing action. As the founding member of the triptan class and a low-cost generic, it retains a place of respect and heavy everyday use.